Regulation of psychotropic fixed dose combination drugs in India: a retrospective longitudinal study (Regulation of psychotropic FDCs in India)

14/02/2022
12/04/2022
EU PAS number:
EUPAS45738
Study
Ongoing
Study identification

EU PAS number

EUPAS45738

Study ID

46707

Official title and acronym

Regulation of psychotropic fixed dose combination drugs in India: a retrospective longitudinal study (Regulation of psychotropic FDCs in India)

DARWIN EU® study

No

Study countries

India
United Kingdom

Study description

Fixed dose combination (FDC) products contain two or more drugs. Few clinical studies have considered the use of FDCs in psychiatry. FDCs containing psychotropic drugs, including combinations not approved by the Indian central regulator, are widely available in India. The Indian government has been attempting to ban the sale of FDCs lacking central approval since 2007. This study aims to assess the impact of the efforts to regulate psychotropic FDC sales.

Study status

Ongoing
Research institutions and networks

Institutions

Population Health Sciences Institute
Public Health Foundation of India Delhi, India, The William Harvey Research Institute, Queen Mary University of London London, UK

Contact details

Bogowicz Paul

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

No funding
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable